Does oral creatine supplementation enhance recovery from a worsening of chronic bronchitis?

Not Applicable

Completed

• Conditions: Chronic obstructive pulmonary disease (COPD); Respiratory; Chronic obstructive pulmonary disease

• Registration Number: ISRCTN22287730
• Lead Sponsor: niversity of Glasgow (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-03-19
• Last Update Posted: 3 July 2017

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

1. Chronic obstructive pulmonary disease (COPD)
2. Acute exacerbation COPD

Exclusion Criteria

1. Alternative diagnosis for acute presentation
2. Active cardiac, neurological, neoplastic disease
3. Diabetes
4. Significant locomotor disease
5. Renal or hepatic impairment
6. Persisting decompensated respiratory acidosis
7. Depressed cognitive function
8. Terminal condition
9. Pregnant, lactating, or wish to become pregnant
10. Implanted cardiac pacemaker resynchronise or defibrillator device
11. Enteral route contraindicated

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fat free mass, measured at baseline and after treatment (2/52; or 42 doses)

Secondary Outcome Measures

Name	Time	Method
1. Anthropometry<br>2. Hand-grip and strength<br>3. Maximal expiratory pressure (MEP)/maximal inspiratory pressure (MIP)/sniff nasal inspiratory pressure (SNIP)<br>4. Rise to go test<br>5. Six minute walk test (SMWT)<br>6. High sensitivity C-reactive protein (hsCRP)<br>7. Interleukin-six (IL-6)<br>8. Tumour necrosis factor-alpha (TNF-a)<br>9. Digit span<br>10. Medical Research Council (MRC) dyspnoea scale<br>11. Hospital Anxiety and Depression (HAD) score<br>12. London Chest Activity of Daily Living (LCADL) score<br>13. Baseline/Transition Dyspnoea Index (BDI/TDI)<br><br>All endpoints measured at baseline and after treatment (2/52; or 42 doses)